Quantinno Capital Management LP grew its position in Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 390.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 57,560 shares of the company’s stock after buying an additional 45,817 shares during the period. Quantinno Capital Management LP’s holdings in Omnicell were worth $1,921,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in OMCL. Raymond James Financial Inc. bought a new position in Omnicell during the second quarter worth about $26,000. Clearstead Advisors LLC increased its holdings in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after acquiring an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in shares of Omnicell during the fourth quarter worth about $58,000. Parkside Financial Bank & Trust raised its position in shares of Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after purchasing an additional 1,264 shares during the period. Finally, First Horizon Corp lifted its holdings in shares of Omnicell by 54.6% during the 4th quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after purchasing an additional 564 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the company. Zacks Research cut Omnicell from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Wells Fargo & Company reduced their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. KeyCorp lowered their price objective on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Weiss Ratings restated a “hold (c-)” rating on shares of Omnicell in a report on Tuesday, August 4th. Finally, Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Omnicell presently has a consensus rating of “Moderate Buy” and an average target price of $57.86.
Insider Activity
In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the sale, the executive vice president directly owned 112,783 shares of the company’s stock, valued at $4,874,481.26. The trade was a 4.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.92% of the company’s stock.
Omnicell Trading Down 1.2%
NASDAQ OMCL opened at $36.86 on Wednesday. Omnicell, Inc. has a 52 week low of $29.06 and a 52 week high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The stock’s 50 day moving average price is $41.05 and its two-hundred day moving average price is $40.36. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 43.88, a PEG ratio of 1.02 and a beta of 0.98.
Omnicell (NASDAQ:OMCL – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. During the same quarter in the previous year, the firm posted $0.45 earnings per share. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, analysts anticipate that Omnicell, Inc. will post 1.3 earnings per share for the current fiscal year.
Omnicell Profile
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
Featured Stories
- Five stocks we like better than Omnicell
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL – Free Report).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
